<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Xanthine-oxidase inhibitor; Uricosuric drugs; Hyperuricaemia: gout; Allopurinol; Febuxostat; Sulfinpyrazone; Probenecid; Benzbromarone" /><meta name="IX" content="Xanthine-oxidase inhibitor; Uricosuric drugs; Hyperuricaemia: gout; Allopurinol; Febuxostat; Sulfinpyrazone; Probenecid; Benzbromarone" /><title>Long-term control of gout: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP6664-long-term-control-of-gout.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP6664-long-term-control-of-gout.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP6664-long-term-control-of-gout.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP6372-musculoskeletal-and-joint-diseases.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="PHP6373-drugs-used-in-rheumatic-diseases-and-gout.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="PHP6660-gout-and-cytotoxic-induced-hyperuricaemia.htm">10.1.4 Gout and cytotoxic-induced hyperuricaemia</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP6662-colchicine.htm" title="Previous: COLCHICINE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP6669-allopurinol.htm" title="Next: ALLOPURINOL">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Long-term control of gout</h1><?highlighter on?><div id="pC" class="jN"><p id="PHP6665">Frequent recurrence of acute attacks of gout, the presence of tophi, or signs of chronic gouty arthritis may call for the initiation of long-term (‘interval’) treatment. For long-term control of gout the formation of uric acid from purines may be reduced with the xanthine-oxidase inhibitors allopurinol or febuxostat; alternatively the uricosuric drug sulfinpyrazone may be used to increase the excretion of uric acid in the urine. Treatment should be continued indefinitely to prevent further attacks of gout by correcting the hyperuricaemia. These drugs should never be started during an acute attack; they are usually started 1–2 weeks after the attack has settled. The initiation of treatment may precipitate an acute attack, and therefore an anti-inflammatory analgesic or colchicine should be used as a prophylactic and continued for at least one month after the hyperuricaemia has been corrected. However, if an acute attack develops during treatment, then the treatment should continue at the same dosage and the acute attack treated in its own right.</p> <p><strong>Allopurinol</strong> is widely used and is especially useful in patients with renal impairment or urate stones when uricosuric drugs cannot be used; it is <em>not</em> indicated for the treatment of asymptomatic hyperuricaemia. It can cause rashes. </p> <p><strong>Febuxostat</strong> is licensed for the treatment of chronic hyperuricaemia where urate deposition has already occurred; it is <em>not</em> indicated for patients in whom the rate of urate formation is greatly increased, such as in malignant disease or in Lesch-Nyhan syndrome.</p> <div id="PHP6667" class="cI"><p class="cAE">NICE guidance<span><cite><a href="PHP6664-long-term-control-of-gout.htm#ID0EAADLAA" class="tooltip ID0EAADLAA">(1)</a></cite></span></p><h3 class="cT">Febuxostat for the management of hyperuricaemia in patients with gout (December 2008)</h3><p>Febuxostat is recommended as an option for the management of chronic hyperuricaemia in gout only for patients who are intolerant of allopurinol or for whom allopurinol is contra-indicated.</p><p>For the purposes of this guidance, intolerance of allopurinol is defined as adverse effects that are sufficiently severe to warrant discontinuation, or to prevent full dose escalation for optimal effectiveness.</p></div> <p><strong>Sulfinpyrazone</strong> can be used instead of allopurinol, or in conjunction with it in cases that are resistant to treatment. </p> <p><strong>Probenecid</strong> (available from <a title="appendix: Special-order Manufacturers" href="PHP10403-special-order-manufacturers.htm">‘special-order’ manufacturers or specialist importing companies</a>) is a uricosuric drug used to prevent nephrotoxicity associated with cidofovir (<a title="monograph: CIDOFOVIR" href="PHP3857-cidofovir.htm">section 5.3.2.2</a>).</p> <p><strong>Benzbromarone</strong> (available from <a title="appendix: Special-order Manufacturers" href="PHP10403-special-order-manufacturers.htm">‘special-order’ manufacturers or specialist importing companies</a>) is a uricosuric drug that can be used in patients with mild renal impairment.</p> <p>Crystallisation of urate in the urine can occur with the uricosuric drugs and it is important to ensure an adequate urine output especially in the first few weeks of treatment. As an additional precaution the urine may be rendered alkaline.</p> <p>Aspirin and other salicylates antagonise the uricosuric drugs; they do not antagonise allopurinol but are nevertheless <em>not</em> indicated in gout.</p> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP6669-allopurinol"><a href="PHP6669-allopurinol.htm" title="ALLOPURINOL">ALLOPURINOL</a></li><li id="_PHP6673-febuxostat"><a href="PHP6673-febuxostat.htm" title="FEBUXOSTAT">FEBUXOSTAT</a></li><li id="_PHP6675-probenecid"><a href="PHP6675-probenecid.htm" title="PROBENECID">PROBENECID</a></li><li id="_PHP6680-sulfinpyrazone"><a href="PHP6680-sulfinpyrazone.htm" title="SULFINPYRAZONE">SULFINPYRAZONE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP6662-colchicine.htm">Previous: COLCHICINE</a> | <a class="top" href="PHP6664-long-term-control-of-gout.htm#">Top</a> | <a accesskey="]" href="PHP6669-allopurinol.htm">Next: ALLOPURINOL</a> ►</div><ol class="cC"><li class="footnote" id="ID0EAADLAA"><p>The <em>Scottish Medicines Consortium</em> issued similar advice in August 2010</p></li></ol></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>